New Surgical Applicator

Researchers invent inkjet that prints out living skin

This is no horror movie, this is part of a recent presentation at the American College of Surgeons Clinical Congress, where Wake Forest Institute for Regenerative Medicine researchers had a super fun time showing off their results from a printer that uses living cells instead of ink. Fluid based inkjet technology used in the very printers you’ve got in your home or office is used to lay down cells, printing large sections of living tissue down on cut up or damaged areas of the body. These fine folks from the Institute note that “any loss of full-thickness skin of more than 4 cm in diameter will not heal by itself,” and that with this device, (refined and tested extensively, of course,) skin that might have been otherwise damaged horrifically can now be patched up to a much higher level of healthiness. Testing has occurred on mice revealing advanced healing by the second and third week of recovery and complete closure of the skin by the end of week three on wounds that would otherwise still be open to infection.
The printer works with two heads, one that dispenses skin cells mixed with fibrinogen (a blood coagulant) and type I collagen (connective tissue’s main component in scars), the other which sends out thrombin (another coagulant.) Together these create a chemical reaction and form fibrin, another protein that works on the clotting of blood. On top of this is one more layer printed by the printer: keratinocytes – the outer layer of skin we’ve all got right this moment.

Future research will be done on the pigs who, if you know your Gangs of New York lore, are great to practice stabbing on because they’ve got skin that very closely resembles human skin. Will this device ever hit your local wartime hospital or town hospital? Who can tell?

CryoLife Slips To Loss In Q3

(RTTNews) - CryoLife Inc. (CRY: News), an implantable biological medical device and cardiovascular tissue processing company, Thursday reported a loss for the third quarter, compared to a profit last year, mainly reflecting higher expenses.
CryoLife's net loss for the quarter was $3.03 million or $0.11 per share compared to a net income of $1.86 million or $0.07 per share last year.
For the recent third quarter, the company recorded charges of $3.7 million for acquired in-process research and development related to the Starch Medical transaction, $3.6 million related to the impairment of its investment in Medafor common stock and $1.6 million related to HemoStase inventory that the company does not believe that it will be able to distribute.
Excluding these charges, adjusted net income for the quarter was $2.6 million or $0.09 per share. On average, three analysts polled by Thomson Reuters expected the company to earn $0.09 per share in the quarter. Analysts' estimates typically excludes special items.
The Kennesaw, Georgia-based company's total revenues improved slightly to $28.44 million from $28.22 million in the comparable quarter last year. Three analysts were looking for a revenue of $29.30 million.
Total gross margins decreased to 54% from 60% last year, mainly due to the charge related to the write-off of the HemoStase inventory.

Effects of an absorbable polysaccharide hemostat PerClot(r) on fracture healing of the cranial bone